| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Plasminogen activator inhibitor-1 (PAI-1) is associated with the differentiation of fibroblast into myofibroblasts (MF). Fibroblasts in the tumor stroma are called cancer-associated fibroblasts (CAFs). CAFs with MF phenotype promote chemotherapy resistance. Here, we investigated whether inhibition of PAI-1 suppresses the MF phenotype of CAFs and results in increased chemosensitivity in lung cancer. We found that PAI-1 inhibition in CAFs co-cultured with lung cancer cells increased the effects of chemotherapy. Our data suggest that inhibition of PAI-1 increases the chemosensitivity of lung cancer cells by suppressing the MF phenotype of CAFs. Hence, PAI-1 might be a promising therapeutic target for patients with chemoresistant lung cancer with CAFs.
|
